Zogenix: Await Q2 Fintepla Revenue, LGS Approval Before Jumping Back In
ThitareeSarmkasat/iStock via Getty Images
Overview
Zogenix (ZGNX) is developing Fintepla (low-dose fenfluramine) for the treatment of rare and serious pediatric seizures. Fintepla was FDA-approved last June for the treatment of Dravet syndrome
